TCL1: A shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Blood

Volumn 120, Issue 8, 2012, Pages 1613-1623

  Weng, Jinsheng ^a   Rawal, Seema ^a   Chu, Fuliang ^a   Park, Hyun Jun ^a,b   Sharma, Rakesh ^a   Delgado, David A ^a   Fayad, Luis ^a   Fanale, Michelle ^a   Romaguera, Jorge ^a   Luong, Amber ^c   Kwak, Larry W ^a,b   Neelapu, Sattva S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA A2 ANTIGEN; MESSENGER RNA; T CELL LEUKEMIA PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENIC MARGINAL ZONE LYMPHOMA; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84865444909     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-382838     Document Type: Article

References (51)

1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. (Pubitemid 40223656)
2. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-626.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
4. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol. 2008;142(2):179-191. (Pubitemid 351987313)
5. Di Nicola M, Zappasodi R, Carlo-Stella C, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2009;113(1):18-27.
6. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99(5):1517-1526. (Pubitemid 34533020)
7. Navarrete MA, Heining-Mikesch K, Schüler F, et al. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood. 2011;117(5):1483-1491.
8. Bertinetti C, Zirlik K, Heining-Mikesch K, et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 2006;66(8):4496-4502.
9. Neelapu SS, Kwak LW, Kobrin CB, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med. 2005;11(9):986-991. (Pubitemid 41294445)
10. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177. (Pubitemid 29474422)
11. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209-1215.
12. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20):2787-2794.
13. Aggarwal M, Villuendas R, Gomez G, et al. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol. 2009;22(2):206-215.
14. Teitell MA. The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer. 2005;5(8):640-648. (Pubitemid 41081389)
15. Said JW, Hoyer KK, French SW, et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest. 2001;81(4):555-564. (Pubitemid 32298801)
16. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000;60(8):2095-2100. (Pubitemid 30225165)
17. Narducci MG, Fiorenza MT, Kang S-M, et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A. 2002;99(18):11712-11717. (Pubitemid 34994464)
18. Narducci MG, Stoppacciaro A, Imada K, et al. TCL1 is overexpressed in patients affected by adult T-cell leukemias. Cancer Res. 1997;57(24):5452-5456. (Pubitemid 28006745)
19. Hoyer KK, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol. 2005;175(2):864-873. (Pubitemid 41094969)
20. Laine J, Künstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6(2):395-407.
21. Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci U S A. 1998;95(7):3885-3889. (Pubitemid 28173223)
22. Gritti C, Dastot Hln Soulier J, et al. Transgenic mice for MTCP1 develop T-Cell prolymphocytic leukemia. Blood. 1998;92(2):368-373. (Pubitemid 28323696)
23. Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci U S A. 2002;99(22):14392-14397. (Pubitemid 35257682)
24. Ramuz O, Bouabdallah R, Devilard E, et al. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. Int J Oncol. 2005;26(1):151-157.
25. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105(50):19643-19648.
26. Herling M, Patel KA, Weit N, et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009;114(21):4675-4686.
27. + T-cell clones. J Immunol Methods. 2008;331(1-2):13-26.
28. The Oncomine database. http://www.oncomine. org/resource. Accessed February 5, 2009.
29. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 2002;51(4):219-228. (Pubitemid 34493956)
30. Herling M, Patel KA, Hsi ED, et al. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol. 2007;31(7):1123-1129. (Pubitemid 47012310)
31. Guo H-C, Jardetzky TS, Garrettt TPJ, Lane WS, Strominger JL, Wiley DC. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature. 1992;360(6402):364-366. (Pubitemid 23000678)
32. Samino Y, López D, Guil S, Saveanu L, van Endert PM, Del Val M. A long N-terminal-extended Nested Set of Abundant and Antigenic Major Histocompatibility Complex class I natural ligands from HIV envelope protein. J Biol Chem. 2006;281(10):6358-6365. (Pubitemid 43847567)
33. Stryhn A, Pedersen LO, Holm A, Buus S. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur J Immunol. 2000;30(11):3089-3099.
34. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature. 1994;371(6498):626-629. (Pubitemid 24315747)
35. Blanchard N, Shastri N. Coping with loss of perfection in the MHC class I peptide repertoire. Curr Opin Immunol. 2008;20(1):82-88.
36. McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med. 2005;3:35.
37. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
38. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-2127.
39. Chiong B, Wong R, Lee P, et al. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma peptide vaccine. J Immunother. 2004;27(5):368-379. (Pubitemid 39121925)
40. Zwaveling S, Mota SCF, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169(1):350-358. (Pubitemid 34686155)
41. Bijker MS, van den Eeden SJF, Franken KL, Melief CJM, Offringa R, van der Burg SH. CD8+CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179(8):5033-5040.
42. Melief CJM, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351-360. (Pubitemid 351589701)
43. Quintarelli C, Dotti G, Hasan ST, et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011;117(12):3353-3362.
44. Lin M-L, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol. 2008;86(4):353-362. (Pubitemid 351667998)
45. Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature. 2011;471(7340):629-632.
46. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature. 2002;419(6909):845-849. (Pubitemid 35238571)
47. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003;24(2):58-61. (Pubitemid 36120639)
48. Alatrash G, Ono Y, Sergeeva A, et al. The Role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother. 2012;35(4):309-320.
49. Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. 1996;74(6):527-530. (Pubitemid 26231555)
50. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
51. Kang S-M, Narducci MG, Lazzeri C, et al. Impaired T- and B-cell development in Tcl1-deficient mice. Blood. 2005;105(3):1288-1294. (Pubitemid 40170905)